Ad-2341

Phase 1

AAddpharma Inc.

Ad-2341 is one of 9 therapeutic programs targeting Gastritis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

GastritisNot yet recruiting

GastritisPhase 1

Not yet recruiting

Competition

Competitive Landscape

12 competitors in Gastritis

#DrugCompanyPhaseTrials

Prevacid

Takeda

Approved

1 2

Nexium

DDexcel Pharma Technologies Ltd.

Approved

2 3

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

2 4

Takecab

PPhathom Pharmaceuticals, Inc.

Approved

1 5

Amoxil

GGlobal Antibiotics Research and Development Partnership

Entyvio

1 7

Mononuclear Cells

NNational University of Malaysia

Preclinical

1 8

Ad-2341

AAddpharma Inc.

Phase 1

1 9

Talcid

Bayer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Gastritis

NCT07717775

Clinical

Trials by Indication[1]

Gastritis1 trial

A Randomized, Open-label, 6-sequence, 3-period Crossover Clinical Trial to Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adult Volunteers.

Not yet recruiting·AAddpharma Inc.·Phase 1·NCT07717775·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ad-2341. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ad-2341. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Addpharma Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: AAddpharma Inc.

Ad-2341

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Gastritis1 trial

References

Drug Info

Quick Facts

Related News